MARKET

COGT

COGT

Cogent Biosciences Inc
NASDAQ
4.810
-0.170
-3.41%
After Hours: 4.820 +0.01 +0.21% 18:21 05/09 EDT
OPEN
4.980
PREV CLOSE
4.980
HIGH
5.14
LOW
4.810
VOLUME
708.72K
TURNOVER
--
52 WEEK HIGH
12.61
52 WEEK LOW
3.720
MARKET CAP
547.65M
P/E (TTM)
-2.5565
1D
5D
1M
3M
1Y
5Y
1D
Scotiabank Remains a Buy on Cogent Biosciences (COGT)
TipRanks · 3d ago
Cogent Biosciences price target lowered to $7 from $8 at Baird
TipRanks · 3d ago
Cogent Biosciences Advances with Promising Clinical Trials
TipRanks · 3d ago
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), OnKure Therapeutics (OKUR) and Neuronetics (STIM)
TipRanks · 3d ago
Cogent Biosciences reports Q1 results
Seeking Alpha · 4d ago
COGENT BIOSCIENCES INC ENTERED INTO SALES AGREEMENT RELATING TO SALE OF UP TO $50 MLN COMMON STOCK- SEC FILING
Reuters · 4d ago
Cogent Biosciences reports Q1 net loss $72M
TipRanks · 4d ago
BRIEF-Cogent Biosciences Q1 Income From Operations USD -74.933 Million
Reuters · 4d ago
More
About COGT
More
Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
Recently
Symbol
Price
%Change
    CE
  • 51.21
  • -0.97%

Webull offers Cogent Biosciences Inc stock information, including NASDAQ: COGT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COGT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading COGT stock methods without spending real money on the virtual paper trading platform.